Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.33 CAD
Change Today 0.00 / 0.00%
Volume 35.5K
COT On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 3:23 PM 05/27/15 All times are local (Market data is delayed by at least 15 minutes).

critical outcome technologie (COT) Snapshot

Open
C$0.33
Previous Close
C$0.33
Day High
C$0.33
Day Low
C$0.33
52 Week High
06/17/14 - C$0.37
52 Week Low
05/28/14 - C$0.18
Market Cap
38.8M
Average Volume 10 Days
306.2K
EPS TTM
C$-0.04
Shares Outstanding
117.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CRITICAL OUTCOME TECHNOLOGIE (COT)

Related News

No related news articles were found.

critical outcome technologie (COT) Related Businessweek News

No Related Businessweek News Found

critical outcome technologie (COT) Details

Critical Outcome Technologies Inc., a bioinformatics company, is engaged in the discovery and development of small molecules. The company focuses on applying CHEMSAS, a proprietary computer based technology, which identifies, profiles, optimizes, selects, and validates commercially viable drug candidates at the discovery stage of preclinical drug development. It focuses on developing drug candidates for the treatment of various cancers, such as acute myelogenous leukemia, small cell lung, ovarian, endometrial, pancreatic, brain, breast, and colorectal cancers, as well as HIV, multiple sclerosis, Alzheimer’s disease, and methicillin-resistant staphylococcus aureus. Its lead oncology compound is COTI-2, a molecule in Phase I clinical trial. The company is also engaged in the development of Rosalind, which provides personalized oncology drug treatment recommendations to physicians and patients based on the genetic profile of each individual patient’s specific cancer. Critical Outcome Technologies Inc. is headquartered in London, Canada.

6 Employees
Last Reported Date: 07/24/14

critical outcome technologie (COT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$170.0K
Chief Financial Officer
Total Annual Compensation: C$130.0K
Compensation as of Fiscal Year 2014.

critical outcome technologie (COT) Key Developments

Critical Outcome Technologies Inc. Gets U.S. Food and Drug Administration Grants IND to Critical Outcome Technologies for COTI--2, the Company's Activator of Mutant P53 Protein

Critical Outcome Technologies Inc. announced that the U.S. Food and Drug Administration granted investigational new drug status) for COTI-2, the Company's small molecule activator of misfolded mutant p53 protein, in gynecological cancers. The Company plans to commence a Phase 1 clinical trial in the second half of calendar 2015 in partnership with the University of Texas, MD Anderson Cancer Center in Houston. The grant of this IND triggers the issuance of 715,720 common shares of the Company as final payment of contingent share consideration that arose on the acquisition of DDP Therapeutics in November 2007. COTI-2 is a small molecule activator of misfolded mutant p53 protein approved for clinical development. Extensive studies have demonstrated COTI-2's ability to restore mutant p53 function and thus induce cancer cell death in many common p53 mutations. Mutations of the p53 gene are the most common genetic alterations in human cancers, occurring in a wide range of cancers, including ovarian, lung, colorectal, breast, liver, bladder and other cancers. COTI-2's specific protein target, low toxicity, combination effectiveness with standard agents, and potential for longer term outpatient therapy as an oral agent, supports a dramatic change in the treatment of susceptible cancers.

Critical Outcome Technologies Appoints Alison Silva as Independent Director

Critical Outcome Technologies Inc. announced that Ms. Alison Silva has been appointed to the Board of Directors of the company as an independent director, subject to final regulatory approval. Ms. Silva is currently Executive Vice President and Chief Operating Officer (COO) of Synlogic. In this role, she is leading the regulatory strategy, drug development, and operational aspects of the company's focus on the discovery and development of engineered therapeutic microbes.

Critical Outcome Technologies Files Investigational New Drug Application with the FDA for COTI-2

Critical Outcome Technologies Inc. announced the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration s Center for Drug Evaluation and Research (FDA) for COTI-2, a potential breakthrough therapy intended for the treatment of women with gynecological cancers with p53 mutations. Advanced gynecological cancers have a particularly high prevalence rate (as high as 95%) of p53 mutations. The IND application is a complete description of the chemistry, non-clinical pharmacodynamics and pharmacokinetics, safety toxicology, manufacturing and other relevant information related to COTI-2 as a potential treatment for patients with p53 mutations. Subject to the FDA granting the IND application, the company intends to initiate a Phase 1 clinical trial of an oral formulation of COTI-2 in patients with gynecological cancers (cervical, endometrial and ovarian) at the University of Texas MD Anderson Cancer Center in Houston. Extensive preclinical studies have demonstrated COTI-2 s ability to restore mutant p53 function and thus induce cancer cell death in cancers with many common p53 mutations. In the upcoming clinical trial, the company intends to determine primarily the safety of COTI-2, as well as obtain some indications of efficacy, the maximum tolerated-dose and pharmacokinetics in treating gynecological cancers containing p53 mutations in patients who have failed the current first line therapies used in these types of cancers.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COT:CN C$0.33 CAD 0.00

COT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COT.
View Industry Companies
 

Industry Analysis

COT

Industry Average

Valuation COT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 13.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CRITICAL OUTCOME TECHNOLOGIE, please visit www.criticaloutcome.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.